Administration of Anti–IL-10 mAb Blocks Exacerbation of Anemia in Fas-deficient H+L6 Homozygous Mice
Treatments . | Hematocrit values (%) . | Amounts of the autoAb bound to RBCs (mean fluorescence intensity) . | Ig-producing cells (per 105 cells) . |
|---|---|---|---|
| Anti–IL-10 | 37.5 ± 2.5a | 494.4 ± 364.2b | 235.8 ± 173.1b |
| Control Ig | 31.5 ± 0.5 | 1,419.2 ± 497.2 | 660.6 ± 240.2 |
Treatments . | Hematocrit values (%) . | Amounts of the autoAb bound to RBCs (mean fluorescence intensity) . | Ig-producing cells (per 105 cells) . |
|---|---|---|---|
| Anti–IL-10 | 37.5 ± 2.5a | 494.4 ± 364.2b | 235.8 ± 173.1b |
| Control Ig | 31.5 ± 0.5 | 1,419.2 ± 497.2 | 660.6 ± 240.2 |
P < 0.01.
P < 0.02.
Either anti–IL-10 mAb or control rat IgG (100 μg/injection) was injected weekly into Fas-deficient H+L6 homozygous mice. 4 wk after the first injection, hematocrit values (%) were measured. Amounts of the autoAb bound to RBCs were assessed as mean fluorescence intensity of FITC-conjugated anti-IgM Ab bound to RBCs. Numbers of anti-RBC Ab-producing cells in MLN were measured by ELISPOT assay using anti-IgM Ab. Values represent the mean ± SD of five mice in each experimental group. Paired t test values calculated between anti–IL-10 and control rat IgG.